- Data from Phase 2 chronic osteoarthritis pain study of Oral CR845 to be presented in poster session at PAINWeek
STAMFORD, Conn., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at PAINWeek, to be held September 5-9, 2017 in Las Vegas, NV and the American Association of Nurse Anesthetists (AANA) Nurse Anesthesia
Annual Congress, to be held September 8-12, 2017 in Seattle, WA.
Presentations will include clinical trial data for CR845, Cara's first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.
Details for the presentations are as follows:
CR845 Poster Presentation:
|Poster Title: || ||"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the|
Hip or Knee"
|Poster Number: || ||101|
|Date/ Time:|| ||Thursday, September 7, 2017; 6:30-8:30 p.m. PT|
|Presentation Title: || ||"A Potential New Path of Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)"|
|Date/ Time:|| ||Friday, September 8, 2017; 12:30 - 1:30 p.m. PT|
|Moderator:|| ||Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics|
|Faculty:|| ||Michael J. Brennan, M.D., Medical Director, the Pain Center of Fairfield; Senior Attending Physician, Department of Medicine, Bridgeport Hospital;|
Associate Director, Chronic Pain and Recovery Program, Silver Hill Hospital
For information about PAINWeek, visit http://www.painweek.org/.
AANA Nurse Anesthesia Annual Congress
Details for the satellite symposium are as follows:
|Presentation Title: || ||"A Potential New Path of Pain Relief"|
|Date/ Time:|| ||Sunday, September 10, 2017; 4:00 - 5:00 p.m. PT|
|Speakers:|| ||Jackie Rowles, D.N.P., M.B.A., C.R.N.A., A.N.P.-B.C., D.A.A.P.M., F.A.A.N., Director, DNP Nurse Anesthesia Program, Marian University; Associate|
Professor, Leighton School of Nursing; Clinical Instructor, College of Osteopathic Medicine; Adjunct Faculty, Nurse Anesthesia Pain Management Fellowship,
Texas Christian University
| || || |
| || ||Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics|
For information about AANA, visit http://aana2017.com/.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system. CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. In patients with moderate-to-severe CKD-associated pruritus, CR845 has demonstrated its potential to reduce itch and improve quality of life.
Stern Investor Relations, Inc.
Source: Cara Therapeutics Inc.
News Provided by Acquire Media